| Azithromycin | stable angina, in all type of patient | vs placebo | NS | - | NS | - | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.01 [0.88 1.15] | p=1.00 | 0 | 13754 | 6 | Gupta et al, ACADEMIC, WIZARD, ACES, STAMINA (Azithromycin), AZACS, | | Coronary event | no data | | myocardial infarction (fatal and non fatal) | 0.97 [0.82 1.14] | p=1.00 | 0 | 13475 | 4 | ACADEMIC, WIZARD, ACES, AZACS, | | cardiovascular events | no data | | Acute coronary syndrome | 0.97 [0.85 1.10] | p=1.00 | 0 | 12338 | 5 | Gupta et al, ACADEMIC, WIZARD, ACES, STAMINA (Azithromycin), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Gupta et al, 1997 | Azithromycin 500 mg/d for 3 d (28 received 1 course, 12 received 2 courses 3 mo apart) | placebo | Male patients at least 6 mo from documented MI and with titers to Chlamydia pneumoniae >=1:64 | | ACADEMIC, 1999 | Azithromycin 500 mg/d for 3 d then 500 mg/wk for 3 mo | placebo | Patients with CAD and C pneumoniae titers of >=1:16. Patients were at least 5 d from an MI | | WIZARD, 2003 | Azithromycin 600 mg/d for 3 d then 1/wk for 11 wk | placebo | Patients with a history of MI of more than 6 weeks before and with C pneumoniae titers of >=1:16 | | ACES, 2005 | Azithromycin 600 mg/wk for 1 y | placebo | Patients with stable CAD | | STAMINA (Azithromycin), 2002 | Azithromycin 500 mg/d for 3 d plus omeprazole 20 mg 2/d for 1 wk plus metronidazole 400 mg 2/d for 1 wk | placebo | Patients with ACS | | AZACS, 2003 | Azithromycin 500 mg on day 1 followed by 250 mg/d for 4d | placebo | Patients with ACS |
|
| Clarithromycin | stable angina, in all type of patient | vs placebo | NS | NS | NS | NS | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.17 [0.94 1.45] | p=1.00 | 0 | 4521 | 2 | CLARIFY, CLARICOR, | | Coronary event | 1.14 [0.96 1.34] | p=1.00 | 0 | 4373 | 1 | CLARICOR, | | myocardial infarction (fatal and non fatal) | 0.52 [0.18 1.50] | p=1.00 | 0 | 181 | 1 | CLARIFY, | | cardiovascular events | 1.17 [0.99 1.39] | p=1.00 | 0 | 4373 | 1 | CLARICOR, | | Acute coronary syndrome | 1.02 [0.81 1.27] | p=1.00 | 0 | 4521 | 2 | CLARIFY, CLARICOR, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CLARIFY, 2001 | Clarithromycin 500 mg/d for 85 d | placebo | Patients with ACS | | CLARICOR, 2006 | clarithromycin 500 mg/day | placebo | patients with adischarge diagnosis of myocardial infarction or angina pectoris |
|
